The Scottish Medicines Consortium (SMC) has approved Ocrevus (ocrelizumab) as a treatment for primary progressive MS in Scotland.
- have had symptoms of primary progressive MS for less than 15 years and
- are able to walk at least 20 metres, with or without walking aids (up to EDSS 6.5) and
- have evidence of MS inflammatory activity on MRI scans
The MS Trust is delighted that Ocrevus has been approved for primary progressive MS. As the first approved treatment for progressive MS in Scotland, this is a landmark decision. But we know this is just the start. More treatments for progressive MS are still desperately needed, and we will continue to fight to ensure everyone with MS can access the treatments they need.
– David Martin, Chief Executive Officer, MS Trust
Ocrevus was approved as a treatment for primary progressive MS in England last year. Roche is working with the NHS in Wales and Northern Ireland to make Ocrevus available throughout the UK. Ocrevus has also been approved as a treatment for relapsing remitting MS in the UK.
Ocrevus is the first treatment to be approved for NHS treatment of primary progressive MS (PPMS). People with this form of MS experience disability more rapidly than those with other types. Clinical trials have shown that Ocrevus can slow the worsening of disability in early, inflammatory PPMS, with the potential to delay the need for a wheelchair by seven years.
Ocrevus is taken as an intravenous infusion (drip). The first dose is given as two separate infusions, two weeks apart. Further doses are given as one infusion every six months. The most common side effects include infusion-related reactions such as headache, rashes, fever and nausea. Other side effects include infections such as coughs, colds, chest infections and herpes virus infections (such as cold sores or shingles).
Covid-19 vaccines and MS
12 Nov 2020 - 00:00
We speak to a neurologist about whether a future Covid-19 vaccine would be safe and effective for people with MS.
A round-up of research from MS Virtual 2020
4 Nov 2020 - 00:00
An update from the this ECTRIMS and ACTRIMS which is the largest annual MS research conference.
Siponimod (Mayzent) approved for active secondary progressive MS in England and Wales
15 Oct 2020 - 00:00
The MS Trust is delighted that siponimod (Mayzent) has also been approved by NICE in England and Wales.
MS in the Media
20 Nov 2020 - 00:00
- New study for advanced MS
- Campaign for fair benefits during the pandemic
- Stem cells compared to Lemtrada
- DMD use and finances
David Martin appointed Chair of the Neurological Alliance
18 Nov 2020 - 00:00
The MS Trust is delighted to announce that CEO David Martin, has been voted in as Chair of the Neurological Alliance.
My MS and my mental health
16 Nov 2020 - 00:00
In his latest blog, Ian Daly speaks candidly about his own experience with depression and urges others to seek help if needed.